IP Verse

Eisai R&d Management Co., Ltd. opposition analysis

COMPANY ANALYSIS

Patent:

Grant Date:

Oct 25, 2023

Title:

Method For Suppressing Bitterness Of Quinoline Derivative

Oppositions:

Patent:

Grant Date:

Aug 10, 2022

Title:

High-Purity Quinoline Derivative And Method For Manufacturing Same

Oppositions:

Patent:

Grant Date:

May 4, 2022

Title:

Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer

Oppositions:

Patent:

Grant Date:

Jun 30, 2021

Title:

Tumor Therapeutic Agent

Oppositions:

Patent Number	Grant Date	Title	Total Oppositions
EP3263106	Oct 25, 2023	Method For Suppressing Bitterness Of Quinoline Derivative	8
EP3524595	Aug 10, 2022	High-Purity Quinoline Derivative And Method For Manufacturing Same	9
EP3265122	May 4, 2022	Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer	4
EP3338779	Jun 30, 2021	Tumor Therapeutic Agent	1

GENERICS (U.K.) LIMITED

STADA ARZNEIMITTEL AG

MAIWALD GMBH

Feel free to send us a message here and we will get back to you